Nasopharyngeal carcinoma
Conditions
Interventions
Treatment group A:Radiotherapy alone
Treatment group B:Concurrent chemotherapy
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years; 2.Pathologically diagnosed as WHO type II/III nasopharyngeal carcinoma; 3.AJCC 8th T3-4N0-1M0 or T1-4N2-3M0 patients and expected to survive at least 6 months; 4.ECOG PS score: 0-1 points; 5.EBV DNA can be detected before treatment. After 1 course of GP regimen (gemcitabine + cisplatin) induction chemotherapy, EBV DNA is completely remitted (below the detection limit) and there is no rebound after the second and third courses of GP regimen treatment; 6.The main organs function normally and meet the following requirements: Blood routine: (1)HB>=90g/L; (2)ANC >=1.5x10^9/L; (3)PLT >=100x10^9/L. The biochemical inspection meets the following standards: (1)BIL =60ml/min (Cockcroft-Gault formula). 7.The patient signs an informed consent form and is willing to complete the study according to the plan.
Exclusion criteria
Exclusion criteria: 1.Clinical examination or imaging examination found that there is distant metastasis; 2.Head and neck have received radiotherapy or surgery; 3.A history of other malignant tumors or multiple primary tumors at the same time (except skin basal cell carcinoma); 4.Positive pregnancy test for women of childbearing age; 5.Concomitant diseases or conditions affect the safety of patients during normal enrollment or research; 6.Active mental disorders or other mental disorders that affect the patient's ability to sign informed consent and understand; 7.Uncontrolled active infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;overall survival;objective remission rate; | — |
Countries
China
Contacts
Public ContactDu Chengrun
Fudan University Shanghai Cancer Center
Outcome results
None listed